我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
17
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2009
进行中（未招募）
2
11.8%
已完成
8
47.1%
尚未招募
1
5.9%
招募中
4
23.5%
Unknown
暂无批准数据
- Thailand has developed its first domestically produced targeted cancer drugs, IMCRANIB 100 and HERDARA, without foreign technology transfer, marking a historic milestone in pharmaceutical independence. - IMCRANIB 100 targets multiple cancers including chronic myeloid leukemia and gastrointestinal stromal tumors by inhibiting tyrosine kinase enzyme, while HERDARA serves as a cost-effective alternative to trastuzumab for breast cancer treatment. - The breakthrough addresses the financial burden of imported cancer drugs, with trastuzumab previously costing up to 1 million baht per course, significantly improving treatment accessibility under Thailand's universal healthcare system. - Production takes place at Thailand's first internationally certified cancer drug manufacturing facility, established in 2020 at the Royal Pharmaceutical Manufacturing Plant in Chonburi Province.
